Amundi Asset Management US’s Rocket Pharmaceuticals RCKT Stock Holding History

Amundi Asset Management US’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$231K	Buy	+5,200	New	+$286K	﹤0.01%	1454

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Amundi Asset Management US's RCKT Position: Q1 2021 in Review

Amundi Asset Management US opened a new position in Rocket Pharmaceuticals (RCKT) in Q1 2021: 5,200 shares worth $231K. The stake represents ﹤0.01% of the portfolio and ranks #1454 among its holdings.

173 funds tracked by Wall St. Rank hold RCKT as of Q1 2021.

Amundi Asset Management US held 5,200 shares of Rocket Pharmaceuticals worth $231K as of Q1 2021.
Rocket Pharmaceuticals was a new Amundi Asset Management US position in Q1 2021.
Rocket Pharmaceuticals made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1454 holding.
173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.